BaxDUO PREVENT-HF
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure
- Stage
- inclusie
- Medicine
- Baxdrostat
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 30 June 2025
- Last Patient In
- 6 April 2027
- Last Patient Last Visit
- 17 December 2029
Inclusion period, 493 days remaining
National Lead
prof. dr. R.A. de Boer
Cardioloog
Study Director
